Telix has announced that the first patient has been dosed in an early access program in the Netherlands for its investigational positron emission tomography imaging agent TLX250-CDx in clear cell renal cell carcinoma. …
Telix says the first patient dosed in European early access program for TLX250-CDx
December 6, 2023 Australian Biotech
Latest Video
New Stories
-
New Zealand moves again to make it easier to access medicines
July 11, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 July
July 10, 2025 - - Podcast -
'The debate is frustrating but it is an opportunity to amplify acknowledged concerns'
July 10, 2025 - - Latest News -
Medibank to subsidise pharmacogenetic testing for members
July 10, 2025 - - Latest News -
Is this the missing link in pharma engagement strategies?
July 9, 2025 - - Latest News -
Stakeholders welcome medicinal cannabis crackdown
July 9, 2025 - - Latest News -
Might Australia be just a little hypocritical on pharmaceutical tariffs?
July 9, 2025 - - Latest News